Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech ca.finance.yahoo.com/news/bi…

$MRNA PT raised to $90 at TD Cowen The analyst increased the peak INT profit estimate to Moderna to apprx $3.4B in 2035, from prior estimate of $830M

$IBRX Announces Database Lock for Registrational Trial of ANKTIVA Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer. - Topline data expected in November - sBLA submission on track for Q4 businesswire.com/news/home/2…

$ABVX PT lowered to $96 from $118 at Wedbush. Maintains a Neutral rating

Yakira Capital Calls on $RNA to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing Questions decision to raise $50M after shares fell apprx 44% at a valuation near 50% of net cash prnewswire.com/news-releases…

$PALI Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at #UEG26 Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days ir.palisadebio.com/palisade-…

$KZIA initiated with an Outperform at Leerink. PT $30

$RVMD Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib as First-Line Treatment for Patients with Metastatic RAS G12D NSCLC

$RAPP Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024) investors.rapportrx.com/news…

$MRNA PT raised to $220 at BofA

$ENLV Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra - Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trial - Workforce reduced by apprx 60% - Salaries for the management team will be reduced by 20%, and the CEO will be reduced by 40% - Topline Phase 2b six-month endpoint data expected by mid-2027

$CLNN submits NDA seeking accelerated approval of CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS).

$SLN to be acquired by Merck KGaA, Darmstadt, for $20/ADS in Cash

$URGN Announces FDA Acceptance of the NDA for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC PDUFA 06/14/27

$CRMD Announces FDA Acceptance for Priority Review of sNDA for Rezzayo (Rezafungin) for Prophylaxis of Invasive Fungal Diseases. PDUFA Q1'27

$MANE PT raised to $172 at Needham

Hong Kong-listed ​Metis TechBio signs up to $1.1 Billion Deal With $LLY for Drug Delivery Tech metistechbio.com/en/qyxw/253…